NEW YORK, NY / ACCESS Newswire / March 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Biohaven’s pipeline drug BHV-7000 has failed to meet the primary endpoint in a pivotal Phase II/III bipolar trial, sinking ...

Biohaven in recent months has reported a clinical stumble in spinal muscular atrophy, alongside a Phase I readout for its ...

Biohaven stock tumbled for the second day running Tuesday after its bipolar mania treatment failed in a three-week study.Analysts called the stock reaction overdone, while Chief Executive Vlad Coric ...

Royal Bank of Canada restated their outperform rating on shares of Biohaven (NYSE:BHVN – Free Report) in a report published ...

Robert Lenz is leaving the brain drug developer to “pursue other interests.” Elsewhere, Atara is cutting half of its staff ...

Biohaven’s bipolar disorder candidate has failed to improve mania symptoms in a phase 2/3 trial. | Biohaven’s bipolar ...

Biohaven Ltd. (NYSE:BHVN – Get Free Report) fell 6.1% during mid-day trading on Monday after the company announced weaker ...

Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, ...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Biohaven fair value estimate is US$28.35 With US$31.37 ...

Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of total IgG, differentiating Biohaven's new small-molecule class of degraders from the monoclonal ...

Following Pfizer’s acquisition, Biohaven’s valuation skyrocketed under Vlad Coric. Find out why BHVN stock’s growth potential ...